Multiple Myeloma Clinical Trial

Clinical Trial Finder Multiple Myeloma Trials

Study of SGN-40, Lenalidomide, and Dexamethasone in Patients With Multiple Myeloma

See Locations Near You

Summary

This is a Phase I, open-label, multi-dose trial to define the MTD and tolerability of a regimen including lenalidomide, dexamethasone, and intravenous SGN-40 in patients with relapsed multiple myeloma.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Diagnosis of multiple myeloma.
Received at least one prior systemic therapy other than single-agent corticosteroids.
Measurable disease of monoclonal protein greater than or equal to 0.5 gram/dL in plasma or 0.5 gram/24 hr urine collection, or greater than 10 mg/dL free light chain (FLC) in serum as determined by serum FLC assay and provided the serum FLC ratio is abnormal.

Exclusion Criteria:

Received an allogenic stem cell transplant.
Previous intolerance of lenalidomide or dexamethasone.
Primary invasive malignancy (other than multiple myeloma) within the last 3 years.

Study is for people with:

Multiple Myeloma

Phase:

Phase 1

Estimated Enrollment:

36

Study ID:

NCT00525447

Recruitment Status:

Completed

Sponsor:

Seagen Inc.

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 9 Locations for this study

See Locations Near You

Rocky Mountain Cancer Center
Denver Colorado, 80218, United States
H. Lee Moffitt Cancer Center & Research Institute
Tampa Florida, 33612, United States
Dana Farber Cancer Institute
Boston Massachusetts, 02115, United States
Barbara Ann Karmanos Cancer Institute
Detroit Michigan, 48201, United States
Nebraska Methodist Hospital
Omaha Nebraska, 68114, United States
Hackensack University Medical Center
Hackensack New Jersey, 07601, United States
Weill Medical College of Cornell University
New York New York, 10021, United States
Avera Cancer Institute
Sioux Falls South Dakota, 57105, United States
Baylor University Medical Center
Dallas Texas, 75246, United States
Load More

How clear is this clinincal trial information?

Study is for people with:

Multiple Myeloma

Phase:

Phase 1

Estimated Enrollment:

36

Study ID:

NCT00525447

Recruitment Status:

Completed

Sponsor:


Seagen Inc.

How clear is this clinincal trial information?

Clinical Trial Resources

Why I’d Choose a Clinical Trial For Myself
SurvivorNet’s Guide To Clinical Trials: What Are They And Are They Right for You?
Clinical Trials Can be Life-Saving for Some
×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider